Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Terminated 1Not yet recruiting 1Enrolling by invitation 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

pembrolizumab 29Carboplatin 15Cisplatin 13Nivolumab 12atezolizumab 10Radiotherapy 10Paclitaxel 10Ipilimumab 10venetoclax 9Pemetrexed 9Docetaxel 9durvalumab 8Gemcitabine 8fludarabine 7Specimen Handling 7Cyclophosphamide 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6enzalutamide 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × futibatinib × 90 days × Clear all
NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 10 charts
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡